Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Gestational Trophoblastic Disease Market Growth Potential: How Will Market Size Change Through 2030?

The market for gestational trophoblastic disease has experienced consistent expansion lately. Projections indicate a rise from $2.16 billion in 2025 to $2.26 billion in 2026, reflecting a compound annual growth rate of 4.6%. Factors contributing to this growth during the past period include advancements in gynecologic oncology, the accessibility of hCG testing, increased adoption of surgical interventions, heightened public awareness regarding rare pregnancy conditions, and the implementation of clinical oncology protocols.

The global market for gestational trophoblastic disease is projected for robust expansion over the coming years, anticipating a reach of $2.81 billion by 2030, propelled by a compound annual growth rate of 5.7%. This anticipated surge in the forecast period stems from advancements in diagnostic precision, the proliferation of oncology facilities, the establishment of uniform therapeutic protocols, enhanced accessibility to medical services, and a concentrated effort on addressing rare disease conditions. Key developments shaping this market during the forecast horizon involve enhanced monitoring through hCG-based methods, a growing reliance on chemotherapy for managing GTD, a heightened emphasis on prompt diagnosis, the broadening scope of specialized oncology care for women, and more effective surveillance following treatment.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13271&type=smp

Gestational Trophoblastic Disease Market Expansion Drivers: What Is Shaping Future Growth?

Anticipated increases in infertility are poised to fuel the expansion of the gestational trophoblastic disease market. Infertility is defined as the inability of a couple or individual to achieve a pregnancy after a year of regular, unprotected intercourse, and its rising incidence is largely attributed to factors such as advanced maternal and paternal age, which negatively impacts egg and sperm viability and increases conception-related complications. While a pathological condition itself, gestational trophoblastic disease offers a unique perspective on fertility challenges, shedding light on how trophoblastic tissue influences implantation and hormonal regulation, thereby informing strategies to enhance conception success. Reflecting this global concern, the World Health Organization reported in April 2023 that approximately 17.5% of adults worldwide, or about one in six individuals, experience infertility, underscoring an urgent global need for more accessible and high-quality fertility treatments. Consequently, the escalating rates of infertility are a significant driver for the gestational trophoblastic disease market.

The escalating trend of cigarette smoking is anticipated to stimulate the expansion of the market for gestational trophoblastic disease. Cigarette smoking, characterized by the inhalation of tobacco smoke laden with harmful chemicals and toxins, can adversely affect numerous bodily systems. It is theorized that smoking may inflict DNA damage upon trophoblastic cells, crucial for placental development, potentially leading to aberrant cellular growth and division, and consequently, gestational trophoblastic disease. Illustrating this concern, a study highlighted by the European Respiratory Society in October 2024 indicated a substantial increase in smoking among young individuals, with reported rates rising from 22.5% in 2022 to 40.1% in 2024. Therefore, the mounting prevalence of cigarette smoking is contributing to the growth of the gestational trophoblastic disease market.

The increasing occurrence of chronic health conditions among mothers is expected to be a catalyst for the growth of the gestational trophoblastic disease market. These chronic conditions, persisting before, during, or after pregnancy, encompass ailments such as diabetes, hypertension, heart disease, and autoimmune disorders, all of which can negatively impact both maternal and fetal well-being. Poor dietary habits and inadequate nutrition are significant contributors to the rising incidence of these chronic diseases, leading to conditions like obesity, hypertension, and other metabolic irregularities before and during gestation. Gestational trophoblastic disease can worsen pre-existing chronic conditions in mothers by disrupting hormonal balance and causing vascular complications that further strain their health. Evidence from the UK’s Office for Health Improvement and Disparities in December 2024 revealed that 26.2% of women in early pregnancy were identified as obese in 2024, a slight increase from the 25.4% recorded the preceding year. Consequently, the growing prevalence of chronic diseases in mothers is a key driver for the gestational trophoblastic disease market.

Gestational Trophoblastic Disease Market Segment Outlook: Which Categories Are Expanding The Fastest?

The gestational trophoblastic disease market covered in this report is segmented –

1) By Type: Hydatidiform Mole, Choriocarcinoma, Placental-Site Trophoblastic Tumor, Epithelioid Trophoblastic Tumor, Other Types

2) By Treatment: Surgery, Chemotherapy, Suction Dilation And Curettage (D&C), Radiation Therapy

3) By End User: Hospital And Clinics, Diagnostic Centers, Other End Users

Subsegments:

1) By Hydatidiform Mole: Complete Hydatidiform Mole, Partial Hydatidiform Mole

2) By Choriocarcinoma: Non-Metastatic Choriocarcinoma, Metastatic Choriocarcinoma

3) By Placental-Site Trophoblastic Tumor: PSTT With Normal Placentation, PSTT With Abnormal Placentation

4) By Epithelioid Trophoblastic Tumor: Epithelioid Trophoblastic Tumor With No Evidence Of Metastasis, Epithelioid Trophoblastic Tumor With Metastasis

5) By Other Types: Trophoblastic Tumor Of Unknown Origin, Non-Gestational Trophoblastic Neoplasia

Gestational Trophoblastic Disease Market Key Companies And Competitive Benchmarking

Major companies operating in the gestational trophoblastic disease market are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sun Pharmaceutical Industries Ltd., GSK plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd.

Access The Complete Gestational Trophoblastic Disease Market Report:

https://www.thebusinessresearchcompany.com/report/gestational-trophoblastic-disease-global-market-report

Gestational Trophoblastic Disease Market Global Footprint: Which Region Holds Market Leadership?

Asia-Pacificwas the largest region in the gestational trophoblastic disease market in 2025, and is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational trophoblastic disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model